This discovery led to the proposal of LEAP2 as a new potential therapeutic target for uncontrolled ghrelin signaling-related diseases, such as obesity and diabetes, cachexia, anorexia, alcohol abuse, and Prader-Willi Syndrome. The gene discussed is LEAP2; the disease is obesity due to melanocortin 4 receptor deficiency.